Clinical trial
Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of…
NCT00369239 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00369239 |
|---|---|
| Title | Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis |
| Official title | Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta? |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | risperidone long acting injectable |
| Enrollment | 303 |
| Start date | Mar 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Aug 29, 2006 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: